3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neoplasms
5
Lung Neoplasms
4
Glioblastoma
3
Urinary Bladder Neoplasms
2
Glioma
2
Brain Neoplasms
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Tuberculosis, Pulmonary
1
Thyroid Nodule
1
Stomach Neoplasms
1
Solitary Pulmonary Nodule
1
Pulmonary Fibrosis
1
Pulmonary Embolism
1
Pulmonary Disease, Chronic Obstructive
1
Pulmonary Arterial Hypertension
1
Pleural Neoplasms
1
Pancreatic Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Pulmonary Nodules
1
Mesothelioma
1
Lung Injury
1
Lung Diseases, Interstitial
1
Lung Diseases
1
Lung Abscess
1
Esophageal Neoplasms
1
Emphysema
1
Disease
1
Cystic Fibrosis
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
15
Pemetrexed
15
Cisplatin
12
Nivolumab
9
Carboplatin
8
Ipilimumab
7
tazemetostat
3
fludarabine
3
anetumab ravtansine
3
Cyclophosphamide
3
spartalizumab
2
budigalimab
2
belinostat
2
atezolizumab
2
amatuximab
2
Vinorelbine
2
Paclitaxel
2
Gemcitabine
2
Docetaxel
2
venetoclax
1
vandetanib
1
trametinib
1
tocilizumab
1
tislelizumab
1
sotorasib
1
ruxolitinib
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma
×
Drug Delivery Systems
×
Clear all
NCT00748085
2015-07-23
ICEtheMAD
CSA Medical, Inc.
Phase NA
Terminated
5 enrolled
5 charts